DAVENPORT & Co LLC Sells 8,293 Shares of Abbott Laboratories $ABT

DAVENPORT & Co LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 0.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 941,488 shares of the healthcare product maker’s stock after selling 8,293 shares during the period. DAVENPORT & Co LLC owned about 0.05% of Abbott Laboratories worth $118,049,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories in the third quarter valued at $31,000. Delos Wealth Advisors LLC acquired a new stake in Abbott Laboratories in the 2nd quarter valued at $32,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at $33,000. Finally, Copia Wealth Management bought a new stake in Abbott Laboratories during the 3rd quarter worth about $38,000. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABT has been the subject of several analyst reports. Citigroup decreased their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Piper Sandler dropped their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Argus decreased their price target on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Barclays lowered their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Finally, BTIG Research cut their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Price Performance

NYSE:ABT opened at $104.10 on Wednesday. Abbott Laboratories has a 12-month low of $102.41 and a 12-month high of $139.06. The firm has a market capitalization of $181.31 billion, a price-to-earnings ratio of 27.98, a P/E/G ratio of 1.67 and a beta of 0.74. The stock’s 50 day moving average price is $111.95 and its two-hundred day moving average price is $122.57. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the company posted $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Buying and Selling

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.